BPG is committed to discovery and dissemination of knowledge
Case Control Study
©The Author(s) 2026.
World J Clin Oncol. Feb 24, 2026; 17(2): 114622
Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.114622
Table 11 Immune profiles by Barcelona Clinic Liver Cancer Stage in hepatocellular carcinoma patients, mean ± SD/median (interquartile range)/n (%)
Parameter
Early stage (BCLC A/B, n = 10)
Advanced stage (BCLC C/D, n = 40)
t/Z/χ2
P value
CD4/PD-1 (%)33.50 ± 0.5036.00 ± 0.40t = -15.00< 0.001b
CD8/TIM-3 (%)15.50 ± 0.5017.80 ± 0.40t =-14.50< 0.001b
AFP (ng/mL)10000 (8000-12000)14000 (12000-15000)Z =-3.50< 0.001b
Mortality1 (10)16 (40)χ2 = 4.20 0.040a


Write to the Help Desk